Related Experiment Video

Updated: Aug 6, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K

Valsartan in the treatment of heart attack survivors

Bodh I Jugdutt1

  • 1Walter Mackenzie Health Sciences Centre, Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. bjugdutt@ualberta.ca

Vascular Health and Risk Management
|February 27, 2007
PubMed

Insights

Survivors of myocardial infarction (MI) face high risks. Angiotensin II receptor blockers (ARBs) like valsartan offer effective secondary prevention, reducing mortality and morbidity post-MI.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Survivors of myocardial infarction (MI) are at significant risk for disability and death.
  • Infarct-related complications include heart failure, cardiac remodeling, and arrhythmias.
  • Angiotensin II (Ang II), a key renin-angiotensin-aldosterone system (RAAS) molecule, contributes to these complications.

Purpose of the Study:

  • To review evidence favoring valsartan for secondary prevention in post-MI survivors.
  • To compare the efficacy of Angiotensin II receptor blockers (ARBs) with ACE inhibitors.

Main Methods:

  • Review of major clinical trials (VALIANT, Val-HeFT).
  • Analysis of data comparing ARBs (specifically valsartan) to ACE inhibitors.
  • Assessment of outcomes in high-risk post-MI patients with left ventricular systolic dysfunction and/or heart failure.

Main Results:

  • Angiotensin receptor blockers (ARBs) provide more complete blockade of Ang II effects at the AT1 receptor.
  • Valsartan demonstrated efficacy comparable to ACE inhibitors in reducing mortality and morbidity.
  • Evidence supports valsartan's role in secondary prevention for post-MI survivors.

Conclusions:

  • RAAS inhibition is crucial for managing post-MI complications.
  • Valsartan is a viable and effective option for secondary prevention after myocardial infarction.
  • ARBs offer a valuable therapeutic strategy in high-risk post-MI populations.

More Related Videos

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 17, 2014

35.9K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...